<DOC>
	<DOCNO>NCT02631044</DOCNO>
	<brief_summary>This open-label Phase 1 study evaluate safety , PK , antitumor activity modify T cell ( JCAR017 ) administer adult patient relapse refractory B-cell NHL . The dose schedule JCAR017 evaluate modify , need , safety antitumor activity . We also determine long modify T cell stay patient 's body well JCAR017 work treat patient non-Hodgkin 's lymphoma whose disease come back responded treatment .</brief_summary>
	<brief_title>Study Evaluating Safety Pharmacokinetics JCAR017 B-cell Non-Hodgkin Lymphoma ( NHL )</brief_title>
	<detailed_description>This open-label , multicenter Phase 1 study determine safety , pharmacokinetics ( PK ) , antitumor activity JCAR017 adult patient relapse refractory diffuse large B cell lymphoma ( DLBCL ) , primary mediastinal B-cell lymphoma ( PMBCL ) , follicular lymphoma Grade 3B , mantle cell lymphoma ( MCL ) . This study evaluate refine dose schedule JCAR017 optimize safety antitumor activity . Upon successful generation JCAR017 product , participant receive treatment one cycle JCAR017 therapy . Each cycle include lymphodepleting chemotherapy follow one two dos JCAR017 administer intravenous ( IV ) injection . The follow-up period participant approximately 24 month final JCAR017 infusion . Long-term follow-up survival , toxicity , viral vector safety continue separate long-term follow-up protocol per health regulatory authority guideline , currently 15 year last JCAR017 infusion .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>1 . Age â‰¥18 year 2 . Relapsed refractory Bcell NHL , include a. DLBCL cohort : DLBCL , otherwise specify ( NOS ) , per WHO classification , include transform DLBCL indolent histology ( tDLBCL ) , primary mediastinal Bcell lymphoma ( PMBCL ) , follicular lymphoma Grade 3B . Subjects must treat anthracycline rituximab ( CD20targeted agent ) one following : i. Biopsyproven refractory disease frontline chemoimmunotherapy ii . Relapsed refractory disease least 2 line therapy autologous hematopoietic stem cell transplant ( autoHSCT ) ; subject tDLBCL must receive least 1 line therapy transformation DLBCL . iii . Relapsed refractory disease allogeneic hematopoietic stem cell transplant ( alloHSCT ) b. MCL cohort : Mantlecell lymphoma relapse refractory disease least 1 prior line MCL therapy 3 . Measureable , PETpositive disease Lugano classification 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 5 . Adequate bone marrow , renal , hepatic , pulmonary , cardiac function 6 . Adequate vascular access leukapheresis procedure 7 . Participants receive previous CD19targeted therapy must CD19positive lymphoma confirm biopsy since complete prior CD19targeted therapy . 1 . Active central nervous system ( CNS ) involvement malignancy 2 . History primary malignancy remission least 2 year ( The follow exempt 2year limit : nonmelanoma skin cancer , curatively treat localized prostate cancer , cervical carcinoma situ biopsy squamous intraepithelial lesion Pap smear ) 3 . Treatment alemtuzumab within 6 month leukapheresis fludarabine cladribine within 3 month leukapheresis 4 . Active hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) infection 5 . Uncontrolled systemic fungal , bacterial , viral , infection 6 . Presence graftvshost disease ( GVHD ) 7 . History cardiovascular disease 8 . History presence clinically relevant CNS pathology 9 . Pregnant nursing woman 10 . Use follow : 1 . Therapeutic dos corticosteroid within 7 day leukapheresis 72 hour prior JCAR017 administration . Physiologic replacement , topical , inhaled steroid permit . 2 . AlloHSCT within 90 day leukapheresis 3 . Donor lymphocyte infusion ( DLI ) within 6 week prior JCAR017 administration 4 . GVHD therapy within 4 week leukapheresis JCAR017 administration 5 . Cytotoxic chemotherapeutic agent within 1 week leukapheresis . Oral chemotherapeutic agent allow least 3 halflives elapse prior leukapheresis . 6 . Lymphotoxic chemotherapeutic agent within 2 week leukapheresis 7 . Experimental agent within 4 week leukapheresis unless progression document therapy least 3 halflives elapse prior leukapheresis 8 . Radiation within 6 week leukapheresis . Subjects must progressive disease irradiated lesion additional nonirradiated , positron emission tomography ( PET ) positive lesion eligible . 11 . Prior CAR Tcell geneticallymodified Tcell therapy , exception prior JCAR017 treatment protocol subject receive retreatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>JCAR017</keyword>
	<keyword>chimeric antigen receptor</keyword>
	<keyword>non-Hodgkin lymphoma</keyword>
	<keyword>CAR</keyword>
	<keyword>CAR T cell</keyword>
	<keyword>autologous T cell therapy</keyword>
	<keyword>cell therapy</keyword>
	<keyword>NHL</keyword>
</DOC>